SecBot SecBot
144 ·Filed Jun 4, 2026

XERS

Xeris Biopharma Holdings, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed5mo ago SEC0001950047-26-005664
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine director diversification sale following RSU vesting. The dollar amount is negligible relative to market cap. No actionable signal for traders, monitor for any follow-on insider selling patterns in future Form 4 filings.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$6.18
T+0 close · Jun 4, 2026 · via day close
Latest settled
+36.57%
T+60 · $8.44
Vs SPY
+32.57%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 5 $6.18entry
  2. T+1 · 5mo ago +0.97%α +0.74% · $6.24
  3. T+5 · 5mo ago +9.87%α +9.30% · $6.79
  4. T+20 · 4mo ago +35.44%α +33.58% · $8.37
  5. T+60 · 3mo ago +36.57%α +32.57% · $8.44

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Director Dawn Halkuff filed a Form 144 notice of intent to sell 20,000 shares of Xeris Biopharma common stock, with an estimated aggregate market value of $117,800. The shares were acquired via restricted stock unit vesting on June 3, 2026. This is a relatively small proposed sale relative to the company's $1.0B market cap and represents a routine diversification move by a director, not a material signal of insider concern.

Key Facts

  • Director Dawn Halkuff filed Form 144 to sell 20,000 shares of XERS common stock.
  • Estimated aggregate market value of the proposed sale is $117,800.
  • Shares were acquired via restricted stock unit vesting on June 3, 2026.
  • The sale represents approximately 0.012% of the company's $1.0B market cap.
  • The filing is an advance notice of intent to sell; the sale may not be executed.

Financial Impact

Proposed sale of $117,800 in XERS common stock by a director, immaterial relative to $1.0B market cap.

dilution

Risk Factors

  • If the sale is executed, it could be followed by additional insider sales, though the current amount is too small to be concerning.
  • No other material risks identified from this filing alone.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-005664
Document: 0001950047-26-005664-index.html0001950047-26-005664
Document: 0001950047-26-005664.txt0001950047-26-005664

US Market Status

Market Closed · Opens in 5h 55m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 4, 2026